Person:
SÜMBÜL, BİLGE

Profile Picture
Status
Organizational Units
OrgUnit Logo
Organizational Unit
Job Title
First Name
BİLGE
Last Name
SÜMBÜL
Name
Email Address
Birth Date

Filters

2020 - 20212
Reset filters

Settings

Type: Article × Author: DOYMAZ, MEHMET ZIYA × Subject: COVID-19 ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19
    (2020-09-25T00:00:00Z) Koç, Mm; Kalkan, Yazıcı; Çetin, Nesibe Selma; Doymaz, Mz; Sümbül, B; Durdu, B; YAZICI, MERVE; MERİÇ KOÇ, MELİHA; ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; OKAY, GÜLAY; DURDU, BÜLENT; SÜMBÜL, BİLGE; DOYMAZ, MEHMET ZIYA
    The recent pandemic of COVID-19 has caused a tremendous alarm around the world. Details of the infection process in the host have significant bearings on both recovery from the disease and on the correlates of the protection from the future exposures. One of these factors is the presence and titers of neutralizing Abs (NAbs) in infected people. In the current study, we set out to investigate NAbs in the recovered subjects discharged from the hospital in full health. Serum samples from a total of 49 documented consecutive COVID-19 subjects were included in the study. All the subjects were adults, and serum samples collected during the discharge were tested in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests against viral Ags. Even though a majority of the recovered subjects had raised significant NAb titers, there is a substantial number of recovered patients (10 out of 49) with no or low titers of NAbs against the virus. In these cohorts as well as in patients with high NAb titers, viral Ag binding Abs were detectable in EIA tests. Both NAb titers and EIA detectable Abs are increased in patients experiencing a severe form of the disease, and in older patients the Ab titers were heightened. The main conclusion is that the recovery from SARS-CoV-2 infection is not solely dependent on high NAb titers in affected subjects, and this recovery process is probably produced by a complex interplay between many factors, including immune response, age of the subjects, and viral pathology.
  • Thumbnail Image
    PublicationOpen Access
    Microbiological Diagnosis of COVID-19
    (2021-02-01T00:00:00Z) SÜMBÜL, BİLGE; DOYMAZ, Mehmet Ziya; SÜMBÜL, BİLGE; DOYMAZ, MEHMET ZIYA
    Various tests are used to detect the severe acute respiratory syndrome-coronirus-2 (SARS-CoV-2) virus causing Coronavirus disease-19 (COVID-19) disease. Today, the realtime (RT) -PCR test combined with the reverse-transcription reaction is the gold standard method used to diagnose SARS-CoV-2. This method is referred to as quantitative realtime PCR (RT-qPCR) because it determines not only the presence of SARS-CoV-2 but also the amount of virus in the specimen. Due to the use of virus-specific primers, the specificity of the tests is considered to be 100%. For this test, swab samples taken from the upper respiratory tract such as nasopharyngeal and throat, samples from the lower respiratory tract areas such as sputum and bronchoalveolar lavage fluid, rectal swab, feces, serum and urine samples are preferred. Correct use of personal protective equipment (PPE) by healthcare professionals during sampling and testing is important. Rapid antigen tests used in addition to RT-qPCR test for the diagnosis of SARS-CoV-2 are advantageous due to the theoretical rapid result time and low cost, but the sensitivity of this method is known to be very low. Virus detection in cell cultures can be used to detect SARS-CoV-2, but it is not for routine diagnostic because the results take a long time, require labor, and expertise. Serological tests are frequently used in the diagnosis and follow-up of this disease. These are mainly ELISA, CLIA, immunofluorescence test (IFA), western blot (WB), protein microarray (microarray) and neutralization. ELISA based immunoglobulin (Ig)M and IgG antibody tests have more than 95% specificity in the diagnosis of COVID-19.